What is GLMD's relative strength rating?

GLMD ranks at the 37th percentile over 1 month, 27th percentile over 3 months, 35th percentile over 6 months, 10th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is GLMD in?

GLMD is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is GLMD in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). GLMD benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

How volatile is GLMD?

GLMD currently shows a 20-day average daily range (ADR%) of 11.0%, a 90-day beta versus the S&P 500 of 1.01. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does GLMD have a seasonal pattern?

TickerStance computes GLMD's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what GLMD has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did GLMD last report earnings?

No SEC EDGAR filings are linked to GLMD in the current TickerStance fundamentals database. This can occur for tickers without a matched CIK (some ADRs, ETFs, and recently listed securities) or when the fundamentals pipeline has not yet processed this ticker.

Galmed Pharmaceuticals Ltd. (GLMD) · RS 35

TODAY'S READ · AS OF 2026-08-24

As of 2026-08-24, Galmed Pharmaceuticals Ltd. (GLMD) has a 3-month relative strength percentile of 27 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 39. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 11.0%, relative volume 0.94×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month27pctile

6 month35pctile

1 year10pctile

Classic14IBD pctile

LDR6leadership

0 of 5 lenses lit · avg RS pctile 19

✓ADR%11.0%✓A/DA!RVOL0.94×!$ Vol$295K

COMPUTED · AS OF 2026-08-24

Pattern read

GLMD is in a stage 4 downtrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -10.1% / -27.5%.

Pure factual computation. Not a recommendation. See stage analysis.

Market backdrop

47.8Neutral

Trend30% weight44.9 Breadth30% weight50.6 Leadership20% weight42.4 Macro20% weight59.0 Full stance breakdown →

Evidence · 1 of 3

Receipts behind the read

0 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

37

3m

27

6m

35

1y

10

LDR

—

StageWeinstein stage analysis

Stage 4 · Decline✓

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

A/D ratingaccumulation / distribution

AAccum

RVOL todayvs 50d avg

0.94×

U/D ratiolast 50 sessions

4.17

Breakout volbreakout day vs 50d avg

-28%

50d avg $ volumeliquidity proxy

$295K

Risk profile

How much does it move?

Daily range, ATR, beta, and the math for a 1-ADR stop.

ADR% (20d)avg daily range

11.0%Elevated

ATR(14)14-day EMA

$0.51

ATR%ATR as % of close

12.49%

Beta vs SPY90d rolling

1.01

1-ADR stoprisk from close $4.05

$3.60−11.0%

Fundamentals · GLMD

Does the business back the chart?

No SEC filings on file for this ticker. Fundamentals section requires EDGAR coverage.

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
GLMD
27RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Financials73

Materials64

Industrials55

Real Estate45

Consumer Staples36

RS pctileLagLead

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

CGCCanopy Growth Corporation Common Shares35 SNDLSundial Growers Inc. Common Shares35 MIRMMirum Pharmaceuticals, Inc. Common Stock35 QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares36

§ Seasonality

10y · since 2022

Best monthDec on averageavg +22.71% · 75% win · n 4

Worst monthMar on averageavg -19.09% · 0% win · n 4

GLMD monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	GLMD Jan avg: -0.91% median: -9.13% win: 25% σ: 22.65% n: 4 2022-04-12 → 2026-07-31	GLMD Feb avg: -14.64% median: -18.45% win: 25% σ: 14.70% n: 4 2022-04-12 → 2026-07-31	GLMD Mar avg: -19.09% median: -16.25% win: 0% σ: 9.85% n: 4 2022-04-12 → 2026-07-31	GLMD Apr avg: -3.81% median: 0.00% win: 40% σ: 16.10% n: 5 2022-04-12 → 2026-07-31	GLMD May avg: -4.54% median: 5.14% win: 60% σ: 38.23% n: 5 2022-04-12 → 2026-07-31	GLMD Jun avg: -6.26% median: -25.70% win: 40% σ: 31.38% n: 5 2022-04-12 → 2026-07-31	GLMD Jul avg: -14.46% median: -11.41% win: 40% σ: 30.26% n: 5 2022-04-12 → 2026-07-31	GLMD Aug avg: -16.90% median: -15.23% win: 0% σ: 10.76% n: 4 2022-04-12 → 2026-07-31 (current)	GLMD Sep avg: 13.80% median: -7.40% win: 50% σ: 62.05% n: 4 2022-04-12 → 2026-07-31	GLMD Oct avg: -17.14% median: -19.72% win: 25% σ: 33.91% n: 4 2022-04-12 → 2026-07-31	GLMD Nov avg: -18.89% median: -18.79% win: 0% σ: 10.75% n: 4 2022-04-12 → 2026-07-31	GLMD Dec avg: 22.71% median: 19.85% win: 75% σ: 38.09% n: 4 2022-04-12 → 2026-07-31

Public attention · GLMD

Is the crowd watching?

50/ 100 · vs its own 90-day norm▲ 21 vs 7dOverlooked

Weak relative strength and quiet attention. Little to read here either way.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

News

Reference

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2834

Float6.3Mshares

Shares out1.0Mshares

Market cap$4.2MNano Cap

FAQ

Frequently asked questions

What is GLMD's relative strength rating?: GLMD ranks at the 37th percentile over 1 month, 27th percentile over 3 months, 35th percentile over 6 months, 10th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is GLMD in?: GLMD is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is GLMD in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). GLMD benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is GLMD?: GLMD currently shows a 20-day average daily range (ADR%) of 11.0%, a 90-day beta versus the S&P 500 of 1.01. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does GLMD have a seasonal pattern?: TickerStance computes GLMD's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what GLMD has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.
When did GLMD last report earnings?: No SEC EDGAR filings are linked to GLMD in the current TickerStance fundamentals database. This can occur for tickers without a matched CIK (some ADRs, ETFs, and recently listed securities) or when the fundamentals pipeline has not yet processed this ticker.

Galmed Pharmaceuticals Ltd. (GLMD) — Stance & relative strength

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

Galmed Pharmaceuticals Ltd. (GLMD) — Stance & relative strength

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

§ Seasonality

Is the crowd watching?

Company snapshot

Frequently asked questions

§ Seasonality

Galmed Pharmaceuticals Ltd. (GLMD) — Stance & relative strength

GLMD is not confirmed as a leader. 27 is not yet a leadership-grade RS read, Market Stance is 47.8

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

Galmed Pharmaceuticals Ltd. (GLMD) — Stance & relative strength

GLMD is not confirmed as a leader. 27 is not yet a leadership-grade RS read, Market Stance is 47.8

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

How much does it move?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions